Porter, Ross JMurray, Graeme IPrice, Daniel PPetty, Russell DMcLean, Mairi H2020-06-122020-06-122020-02-18Porter, R J, Murray, G I, Price, D P, Petty, R D & McLean, M H 2020, 'Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype', British Journal of Cancer, vol. 122, pp. 545-554. https://doi.org/10.1038/s41416-019-0685-10007-0920ORCID: /0000-0003-3981-2420/work/76973688ORCID: /0000-0002-7443-2653/work/76974208https://hdl.handle.net/2164/14495The preparation of this paper was funded in part by the Pathological Society of Great Britain and Ireland (intercalated degree educational studentship to R.J.P.). All data is published within this paper and within accompanying supporting files (indicated in text) and accessed via weblink on the journal site.111104536engSDG 3 - Good Health and Well-beingBarrett’s oesophagusoesophageal cancerHMGB1lymphocytesbiomarkerepithelial cellDIAGNOSISGRADE DYSPLASIAMANAGEMENTPROGNOSISADENOCARCINOMACANCERP53THERAPYBRITISH SOCIETYRADIOFREQUENCY ABLATIONR MedicineOncologyCancer ResearchRJournal article10.1038/s41416-019-0685-1http://www.scopus.com/inward/record.url?scp=85076588239&partnerID=8YFLogxK122